BioCentury
ARTICLE | Clinical News

Esperion hits record high on ETC-1002 results

March 18, 2015 1:49 AM UTC

Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) jumped $22.50 (29%) to $99.60, hitting an all-time high on Tuesday after the company said ETC-1002 met the primary endpoint of lowering LDL-cholesterol vs. placebo in a Phase IIb trial to treat hypercholesterolemia.

The 12-week ETC-1002-009 trial enrolled 134 patients on statin therapy. In the study, 120 mg and 180 mg doses of ETC-1002 lowered LDL vs. placebo by 17% (p=0.0055) and 24% (p<0.0001), respectively. Esperion reported no treatment-related serious adverse events (SAEs) or muscle-related AEs. ...